102 research outputs found
Novel Chitinolytic Enzymes with Biological Activity Against Herbivorous Insects
The soil bacteria, Streptomyces albidoflavus, secretes endochitinases and chitobiosidases that are active over a broad range of pH (4-10). Ingestion of this mixture of chitinolytic enzymes significantly reduced the growth and development of Trichoplusia ni and significantly reduced survival of Myzus persicae, Bemisia argentifolii, and Hypothenemus hampei. Perfusion chromatography was used to separate endochitinases from chitobiosidases. The endochitinases had significantly greater biological activity against Bemisia argentifolii than the chitobiosidases. The utility of chitinolytic enzymes as regulators of populations of herbivorous insects is discusse
Genetic test to stop smoking (GeTSS) trial protocol: randomised controlled trial of a genetic test (Respiragene) and Auckland formula to assess lung cancer risk
The STAR care pathway for patients with pain at 3 months after total knee replacement:a multicentre, pragmatic randomised controlled trial
BACKGROUND: Approximately 20% of people experience chronic pain after total knee replacement, but effective treatments are not available. We aimed to evaluate the clinical effectiveness and cost-effectiveness of a new care pathway for chronic pain after total knee replacement. METHODS: We did an unmasked, parallel group, pragmatic, superiority, randomised, controlled trial at eight UK National Health Service (NHS) hospitals. People with chronic pain at 3 months after total knee replacement surgery were randomly assigned (2:1) to the Support and Treatment After Replacement (STAR) care pathway plus usual care, or to usual care alone. The STAR intervention aimed to identify underlying causes of chronic pain and enable onward referrals for targeted treatment through a 3-month post-surgery assessment with an extended scope practitioner and telephone follow-up over 12 months. Co-primary outcomes were self-reported pain severity and pain interference in the replaced knee, assessed with the Brief Pain Inventory (BPI) pain severity and interference scales at 12 months (scored 0–10, best to worst) and analysed on an as-randomised basis. Resource use, collected from electronic hospital records and participants, was valued with UK reference costs. Quality-adjusted life-years (QALYs) were calculated from EQ-5D-5L responses. This trial is registered with ISRCTN, ISRCTN92545361. FINDINGS: Between Sept 6, 2016, and May 31, 2019, 363 participants were randomly assigned to receive the intervention plus usual care (n=242) or to receive usual care alone (n=121). Participants had a median age of 67 years (IQR 61 to 73), 217 (60%) of 363 were female, and 335 (92%) were White. 313 (86%) patients provided follow-up data at 12 months after randomisation (213 assigned to the intervention plus usual care and 100 assigned to usual care alone). At 12 months, the mean between-group difference in the BPI severity score was −0·65 (95% CI −1·17 to −0·13; p=0·014) and the mean between-group difference in the BPI interference score was −0·68 (−1·29 to −0·08; p=0·026), both favouring the intervention. From an NHS and personal social services perspective, the intervention was cost-effective (greater improvement with lower cost), with an incremental net monetary benefit of £1256 (95% CI 164 to 2348) at £20 000 per QALY threshold. One adverse reaction of participant distress was reported in the intervention group. INTERPRETATION: STAR is a clinically effective and cost-effective intervention to improve pain outcomes over 1 year for people with chronic pain at 3 months after total knee replacement surgery. FUNDING: National Institute for Health Research
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell (CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterised. Current practice is guided by physician preference rather than established evidence. Identification of effective BT modalities and factors predictive of response could improve CAR-T intention to treat and clinical outcomes. We assessed BT modality and response in 375 adult LBCL patients in relation to outcomes following axicabtagene ciloleucel (Axi-cel) or tisagenlecleucel (Tisa-cel). The majority of patients received BT with chemotherapy (57%) or radiotherapy (17%). We observed that BT was safe for patients, with minimal morbidity/mortality. We showed that complete or partial response to BT conferred a 42% reduction in disease progression and death following CD19CAR-T therapy. Multivariate analysis identified several factors associated with likelihood of response to BT, including response to last line therapy, the absence of bulky disease, and the use of Polatuzumab-containing chemotherapy regimens. Our data suggested that complete/partial response to BT may be more important for Tisa-cel than Axi-cel, as all Tisa-cel patients with less than partial response to BT experienced frank relapse within 12 months of CD19CAR-T infusion. In summary, BT in LBCL should be carefully planned towards optimal response and disease debulking, to improve CD19CAR-T patient outcomes. Polatuzumab-containing regimens should be strongly considered for all suitable patients, and failure to achieve complete/partial response to BT pre-Tisa-cel may prompt consideration of further lines of BT where possible
Better post-operative prediction and management of chronic pain in adults after total knee replacement:the multidisciplinary STAR research programme including RCT
Background: The treatment of osteoarthritis with knee replacement aims to reduce pain and disability.
However, some people experience chronic pain.
Objectives: To improve outcomes for people with chronic pain after knee replacement by identifying
post-surgical predictors and effective interventions, characterising patient pathways and resource use,
developing and evaluating a new care pathway, and exploring non-use of services.
Design: The programme comprised systematic reviews, national database analyses, a cohort study,
intervention development, a randomised controlled trial, health economic analyses, qualitative studies
and stakeholder engagement. Extensive and meaningful patient and public involvement underpinned all
studies.
Setting: NHS, secondary care, primary care.
Participants: People with, or at risk of, chronic pain after knee replacement and health-care
professionals involved in the care of people with pain.
Interventions: A care pathway for the management of people with pain at 3 months after knee
replacement.
Main outcome measures: Patient-reported outcomes and cost-effectiveness over 12 months.
Data sources: Literature databases, the National Joint Registry, Hospital Episode Statistics, patient-
reported outcomes, the Clinical Practice Research Datalink, the Clinical Outcomes in Arthroplasty Study,
the Support and Treatment After joint Replacement randomised trial, interviews with 90 patients and 14
health-care professionals, and stakeholder events.
Review methods: Systematic reviews of cohort studies or randomised trials, using meta-analysis or
narrative synthesis.
Results: In the Clinical Outcomes in Arthroplasty Study cohort, 14% of people experienced chronic pain 1
year after knee replacement. By 5 years, 65% reported no pain, 31% fluctuated and 4% remained in chronic
pain. People with chronic pain had a worse quality of life, higher primary care costs, and more frequent
analgesia prescriptions, particularly for opioids, than those not in chronic pain. People with chronic pain after
knee replacement who made little or no use of services often felt nothing more could be done, or that further
treatments may have no benefit or cause harm. People described a feeling of disconnection from their
replaced knee. Analysis of UK databases identified risk factors for chronic pain after knee replacement. Pre-
operative predictors were mild knee pain, smoking, deprivation, body mass index between 35 and 40 kg/m2
and knee arthroscopy. Peri- and post-operative predictors were mechanical complications, infection,
readmission, revision, extended hospital stay, manipulation under anaesthetic and use of opioids or
antidepressants. In systematic reviews, pre-operative exercise and education showed no benefit in relation
to chronic pain. Peri-operative interventions that merit further research were identified. Common peri-
operative treatments were not associated with chronic pain. There was no strong evidence favouring specific
post-operative physiotherapy content. We evaluated the Support and Treatment After joint Replacement
care pathway in a multicentre randomised controlled trial. We randomised 363 people with pain at 3 months
after knee replacement from eight NHS Trusts in England and Wales. At 12 months’ follow-up, the
intervention group had lower mean pain severity (adjusted difference –0.65, 95% confidence interval –1.17
to -0.13; p = 0.014) and pain interference (adjusted difference –0.68, 95% confidence interval –1.29 to -0.08;
p = 0.026), as measured on the Brief Pain Inventory subscales (scale 0–10). People receiving the Support and
Treatment After joint Replacement pathway had lower NHS and Personal Social Services costs (–£724, 95%
confidence interval –£150 to £51) and higher quality-adjusted life-years (0.03, 95% confidence interval
–0.008 to 0.06) than those with usual care. The Support and Treatment After joint Replacement pathway
was cost-effective with an incremental net monetary benefit at the £20,000 per quality-adjusted life-year
threshold of £1256 (95% confidence interval £164 to £2348), indicating a 98.79% probability that the
intervention is the cost-effective option. Participants found the Support and Treatment After joint
Replacement pathway acceptable, with opportunities to receive information and discuss concerns while
ensuring further treatment and support. In systematic reviews considering treatments for chronic pain after
surgery we identified some unifactorial interventions that merit further research after knee replacement.
Health-care professionals delivering and implementing the Support and Treatment After joint Replacement
pathway valued its focus on neuropathic pain and psychosocial issues, enhanced patient care, formalised
referrals, and improved pain management. Stakeholders supported pathway implementation.
Limitations: Database analyses were limited to factors recorded in data sets. Pain was only measured 6
months after surgery. However, analyses including large numbers of centres and patients should be
generalisable across the NHS. In many studies found in systematic reviews, long-term pain was not a key
outcome.
Conclusions: The Support and Treatment After joint Replacement pathway is a clinically effective and
cost-effective, acceptable intervention for the management of chronic pain after knee replacement.
Unifactorial interventions merit further study before inclusion in patient care. People with pain should
be empowered to seek health care, with the support of health-care professionals.
Future work: Future work should include research relating to the implementation of the Support and
Treatment After joint Replacement pathway into the NHS, an assessment of its long-term clinical
effectiveness and cost-effectiveness and wider application, and an evaluation of new interventions for
incorporation in the pathway. It will also be important to design and conduct research to improve
communication between patients and health-care professionals before surgery; explore whether or not
education and support can enable earlier recognition of chronic pain; consider research that may identify
how to support people’s feelings of disconnectedness from their new knee; and design and evaluate a
pre-surgical intervention based on risk factors.
Study registration: All systematic reviews were registered on PROSPERO (CRD42015015957,
CRD42016041374 and CRD42017041382). The Support and Treatment After joint Replacement
randomised trial was registered as ISRCTN92545361.
Funding: This project was funded by the National Institute for Health and Care Research (NIHR)
Programme Grants for Applied Research programme and will be published in full in Programme Grants for
Applied Research; Vol. 11, No. 3. See the NIHR Journals Library website for further project information
Identification of cancer risk and associated behaviour: implications for social marketing campaigns for cancer prevention
Background
Community misconception of what causes cancer is an important consideration when devising communication strategies around cancer prevention, while those initiating social marketing campaigns must decide whether to target the general population or to tailor messages for different audiences. This paper investigates the relationships between demographic characteristics, identification of selected cancer risk factors, and associated protective behaviours, to inform audience segmentation for cancer prevention social marketing.
Methods
Data for this cross-sectional study (n = 3301) are derived from Cancer Council New South Wales’ 2013 Cancer Prevention Survey. Descriptive statistics and logistic regression models were used to investigate the relationship between respondent demographic characteristics and identification of each of seven cancer risk factors; demographic characteristics and practice of the seven ‘protective’ behaviours associated with the seven cancer risk factors; and identification of cancer risk factors and practising the associated protective behaviours, controlling for demographic characteristics.
Results
More than 90% of respondents across demographic groups identified sun exposure and smoking cigarettes as moderate or large cancer risk factors. Around 80% identified passive smoking as a moderate/large risk factor, and 40–60% identified being overweight or obese, drinking alcohol, not eating enough vegetables and not eating enough fruit. Women and older respondents were more likely to identify most cancer risk factors as moderate/large, and to practise associated protective behaviours. Education was correlated with identification of smoking as a moderate/large cancer risk factor, and with four of the seven protective behaviours. Location (metropolitan/regional) and country of birth (Australia/other) were weak predictors of identification and of protective behaviours. Identification of a cancer risk factor as moderate/large was a significant predictor for five out of seven associated cancer-protective behaviours, controlling for demographic characteristics.
Conclusions
These findings suggest a role for both audience segmentation and whole-of-population approaches in cancer-prevention social marketing campaigns. Targeted campaigns can address beliefs of younger people and men about cancer risk factors. Traditional population campaigns can enhance awareness of being overweight, alcohol consumption, and poor vegetable and fruit intake as cancer risk factors
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma
The impact of bridging therapy (BT) on CD19-directed chimeric antigen receptor T-cell (CD19CAR-T) outcomes in large B-cell lymphoma (LBCL) is poorly characterized. Current practice is guided through physician preference rather than established evidence. Identification of effective BT modalities and factors predictive of response could improve both CAR-T intention to treat and clinical outcomes. We assessed BT modality and response in 375 adult patients with LBCL in relation to outcomes after axicabtagene ciloleucel (Axi-cel) or tisagenlecleucel (Tisa-cel) administration. The majority of patients received BT with chemotherapy (57%) or radiotherapy (17%). We observed that BT was safe for patients, with minimal morbidity or mortality. We showed that complete or partial response to BT conferred a 42% reduction in disease progression and death after CD19CAR-T therapy. Multivariate analysis identified several factors associated with likelihood of response to BT, including response to last line therapy, the absence of bulky disease, and the use of polatuzumab-containing chemotherapy regimens. Our data suggested that complete or partial response to BT may be more important for Tisa-cel than for Axi-cel, because all patients receiving Tisa-cel with less than partial response to BT experienced frank relapse within 12 months of CD19CAR-T infusion. In summary, BT in LBCL should be carefully planned toward optimal response and disease debulking, to improve patient outcomes associated with CD19CAR-T. Polatuzumab-containing regimens should be strongly considered for all suitable patients, and failure to achieve complete or partial response to BT before Tisa-cel administration may prompt consideration of further lines of BT where possible
The SOS-framework (Systems of Sedentary behaviours): an international transdisciplinary consensus framework for the study of determinants, research priorities and policy on sedentary behaviour across the life course: a DEDIPAC-study.
BACKGROUND: Ecological models are currently the most used approaches to classify and conceptualise determinants of sedentary behaviour, but these approaches are limited in their ability to capture the complexity of and interplay between determinants. The aim of the project described here was to develop a transdisciplinary dynamic framework, grounded in a system-based approach, for research on determinants of sedentary behaviour across the life span and intervention and policy planning and evaluation.
METHODS: A comprehensive concept mapping approach was used to develop the Systems Of Sedentary behaviours (SOS) framework, involving four main phases: (1) preparation, (2) generation of statements, (3) structuring (sorting and ranking), and (4) analysis and interpretation. The first two phases were undertaken between December 2013 and February 2015 by the DEDIPAC KH team (DEterminants of DIet and Physical Activity Knowledge Hub). The last two phases were completed during a two-day consensus meeting in June 2015.
RESULTS: During the first phase, 550 factors regarding sedentary behaviour were listed across three age groups (i.e., youths, adults and older adults), which were reduced to a final list of 190 life course factors in phase 2 used during the consensus meeting. In total, 69 international delegates, seven invited experts and one concept mapping consultant attended the consensus meeting. The final framework obtained during that meeting consisted of six clusters of determinants: Physical Health and Wellbeing (71% consensus), Social and Cultural Context (59% consensus), Built and Natural Environment (65% consensus), Psychology and Behaviour (80% consensus), Politics and Economics (78% consensus), and Institutional and Home Settings (78% consensus). Conducting studies on Institutional Settings was ranked as the first research priority. The view that this framework captures a system-based map of determinants of sedentary behaviour was expressed by 89% of the participants.
CONCLUSION: Through an international transdisciplinary consensus process, the SOS framework was developed for the determinants of sedentary behaviour through the life course. Investigating the influence of Institutional and Home Settings was deemed to be the most important area of research to focus on at present and potentially the most modifiable. The SOS framework can be used as an important tool to prioritise future research and to develop policies to reduce sedentary time
Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between
As more research studies incorporate next-generation sequencing (including whole-genome or whole-exome sequencing), investigators and institutional review boards face difficult questions regarding which genomic results to return to research participants and how. An American College of Medical Genetics and Genomics 2013 policy paper suggesting that pathogenic mutations in 56 specified genes should be returned in the clinical setting has raised the question of whether comparable recommendations should be considered in research settings. The Clinical Sequencing Exploratory Research (CSER) Consortium and the Electronic Medical Records and Genomics (eMERGE) Network are multisite research programs that aim to develop practical strategies for addressing questions concerning the return of results in genomic research. CSER and eMERGE committees have identified areas of consensus regarding the return of genomic results to research participants. In most circumstances, if results meet an actionability threshold for return and the research participant has consented to return, genomic results, along with referral for appropriate clinical follow-up, should be offered to participants. However, participants have a right to decline the receipt of genomic results, even when doing so might be viewed as a threat to the participants’ health. Research investigators should be prepared to return research results and incidental findings discovered in the course of their research and meeting an actionability threshold, but they have no ethical obligation to actively search for such results. These positions are consistent with the recognition that clinical research is distinct from medical care in both its aims and its guiding moral principles
- …